Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

Post-hoc Phase 2 data for EB613 showed greater bone mineral density gains and an anabolic effect among postmenopausal women with osteoporosis (baseline T-scores ≤ -2.5) than among women with osteopenia (T-scores > -2.5). The article provides no numerical effect sizes or further trial details.